by Nicolas Hulscher,Global Research:
Epidemiologist Nicolas Hulscher breaks down the findings on Real America’s Voice
I joined Steve Gruber on Real America’s Voice to break down what is now the largest real-world human analysis of ivermectin and mebendazole in cancer patients.
84.4% of the cancer patients taking ivermectin + mebendazole reported no evidence of disease, tumor regression, or cancer stabilization after 6 months.
That kind of signal doesn’t happen randomly. The key question is not justwhatwe observed, but why.
There are nowhundreds of preclinical studies—in both cell systems and animal models—showing that antiparasitic agents like ivermectin and mebendazole exertbroad, multi-target anti-cancer effects across more than a dozen tumor types.
TRUTH LIVES on athttps://sgtreport.tv/
In other words, the clinical signal we observed is not surprising. It isbiologically coherent. Three mechanisms stand out as central:
First, ivermectin appears to targetcancer stem cells—the small, highly resistant population of cells that drive recurrence and metastasis. Most conventional therapies fail to eliminate these cells. You can shrink a tumor, but if the stem cells remain, the cancer often comes back. Laboratory data suggest ivermectin disrupts this root system.
Second, mebendazole interferes withmicrotubule formation, which is essential for cell division. When you disrupt microtubules, cancer cells lose their ability to replicate effectively. This creates a direct anti-proliferative effect.
Source: SGT Report
